Skip to main content
DONGWHA PHARM.CO.,LTD logo

DONGWHA PHARM.CO.,LTD — Investor Relations & Filings

Ticker · 000020 ISIN · KR7000020008 KO Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2025-02-14 Major Shareholding Noti…
Country KR South Korea
Listing KO 000020

About DONGWHA PHARM.CO.,LTD

https://www.dong-wha.co.kr

Dongwha Pharm is a pharmaceutical company engaged in the research, development, manufacturing, and sale of a diverse range of healthcare products. Its portfolio includes ethical (prescription) pharmaceuticals, over-the-counter (OTC) drugs, medical devices, quasi-drugs, health functional foods, cosmetics, and beverages. The company's research and development efforts focus on various therapeutic areas, including alimentary and cardiovascular systems. Dongwha Pharm actively pursues innovation through its drug pipeline, clinical trials, and strategic investments in emerging fields like digital therapeutics.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the share ownership, changes in holdings, and contractual relationships (such as collateral agreements) of major shareholders and their special related parties. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-02-14 Korean
임원ㆍ주요주주특정증권등거래계획보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Trading Plan for Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주특정증권등거래계획보고서) filed with the Korean financial authorities (Financial Supervisory Service/Korea Exchange). This document outlines a planned transaction (a gift of shares) by a company executive (Chairman Yoon Do-jun of Dong-wha Pharmaceutical). In the context of financial filings, reports detailing personal share transactions or trading plans by directors and executives are classified as 'Director's Dealing'.
2025-02-14 Korean
임원ㆍ주요주주특정증권등거래계획보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Trading Plan for Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 거래계획보고서) filed by an executive (Yoon In-ho) of Dong-A ST. This is a regulatory filing required by the Financial Services Commission and the Korea Exchange in South Korea when an insider plans to trade company shares. While it involves an insider, it is specifically a 'trading plan' report rather than a record of a completed transaction (Director's Dealing). Given the specific nature of this regulatory disclosure regarding future trading plans, it falls under the 'Regulatory Filings' category as the most appropriate fallback.
2025-02-14 Korean
[기재정정]신규시설투자등
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from Dongwha Pharm regarding a 'New Facility Investment' (신규시설투자). It specifically details a correction (정정신고) to the investment period end date for a headquarters reconstruction project. Since this is a specific regulatory announcement regarding capital expenditure and facility investment updates that does not fit into the other specific categories like M&A or Share Issues, it is classified as a general Regulatory Filing (RNS).
2024-12-31 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 1% confidence The document is a short regulatory announcement from Dongwha Pharm regarding the setting of a record date and the closure of the shareholder register for the purpose of the 96th Annual General Meeting. It does not contain the full report or proxy materials, but rather serves as a formal notification of a corporate action. Given the nature of the announcement, it fits best under the general regulatory filing category.
2024-12-16 Korean
[기재정정]주요사항보고서(타법인주식및출자증권양수결정)
M&A Activity Classification · 1% confidence The document is a regulatory filing submitted to the Korea Exchange (KRX) by Dong-Wha Pharmaceutical. It specifically reports the cancellation (withdrawal) of a previously announced acquisition of shares in another company (Hironic). This type of disclosure regarding M&A activity, specifically the termination of a deal, falls under the category of M&A Activity (TAR).
2024-11-25 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.